The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 65 of the 230 sources its claims cite were checked for support.
Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas
Open accessAbstract
Background: Bone and soft-tissue sarcomas are rare, heterogeneous malignancies whose surveillance remains dominated by imaging despite substantial molecular diversity and variable patterns of relapse. Circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) offer minimally invasive approaches for monitoring tumor biology, but their performance in sarcoma depends strongly on subtype, disease burden, assay design, and biological shedding. Methods: This narrative review synthesizes evidence published from 2015 to 2026 on ctDNA and CTCs for baseline risk assessment, treatment-response monitoring, minimal residual disease (MRD) detection, molecular relapse, and integration with imaging-based surveillance in bone and soft-tissue sarcomas. Results: Current evidence supports a genomics-guided framework in which liquid-biopsy strategy is selected according to sarcoma subtype, molecular architecture, and clinical purpose. ctDNA is the most mature analyte, with best-supported evidence in osteosarcoma, where tumor-informed assays predict postoperative relapse, and in translocation-associated sarcomas, where breakpoint-guided assays enable highly specific longitudinal monitoring. Copy-number-based approaches are relevant for complex-karyotype tumors, while mutation-, methylation-, fragmentomic-, and RNA-based strategies may be useful in selected contexts. However, detection rates vary, false-negative results occur in low-shedding or low-volume disease, and clinical utility for changing treatment remains incompletely established. CTCs provide complementary cellular and prognostic information, particularly in osteosarcoma, but remain limited by platform heterogeneity and incomplete standardization. Conclusion: Liquid biopsy may refine risk stratification, support treatment-response assessment, clarify indeterminate imaging findings, and identify molecular relapse in selected sarcoma patients. At present, it should be interpreted as an adjunct to imaging and specialist multidisciplinary care rather than as a replacement for standard radiologic surveillance.
Overview
CoChat Summary
TL;DR
This narrative review argues that liquid biopsy in bone and soft-tissue sarcomas should be “genomics-guided,” meaning the assay should match the tumor’s molecular architecture and the clinical question rather than using one universal platform. ctDNA has the strongest near-term support, especially for baseline risk, treatment response, MRD, and molecular relapse in osteosarcoma and translocation-associated sarcomas, while CTCs are promising but less standardized.
Key findings
- The literature search identified 1284 records; after removing 347 duplicates, 937 titles/abstracts were screened, 124 full texts were assessed, and 53 sources were included in the narrative synthesis.
- In a Children’s Oncology Group cohort, ctDNA was detectable in more than half of newly diagnosed Ewing sarcoma and osteosarcoma cases, and detectable ctDNA was associated with inferior outcomes, particularly in localized Ewing sarcoma.
- In the largest osteosarcoma MRD cohort described, tumor-informed MRD panels were generated in 71 of 83 patients; postoperative ctDNA predicted inferior event-free survival and preceded positive imaging in 5 patients, with a mean lead time of 92.6 days.
- For osteosarcoma CTCs, one study detected CTCs in 30 of 32 patients before treatment (mean 14.06 ± 9.08), another in 28 of 30 patients (median 6 CTCs per 5 mL), and a third found CTCs in 43 of 50 patients with IMP3-positive CTC count showing AUC 0.873, 87.5% sensitivity, and 82.4% specificity for identifying metastasis.
Methods
- Narrative review of circulating biomarkers in bone and soft-tissue sarcomas, focusing on ctDNA, cfDNA, cfRNA, CTCs, and other circulating biomarkers for risk assessment, response monitoring, MRD, relapse surveillance, and imaging integration.
- Structured searches were conducted in PubMed and Scopus for studies published between January 2015 and 1 April 2026, with additional targeted searches and manual reference screening.
- Evidence was synthesized qualitatively; the paper states that it was not a formal systematic review or meta-analysis, and no quantitative meta-analysis was performed.
Limitations
- The paper states that most available studies are small, single-center, heterogeneous, and often retrospective, with variable sampling schedules and limited multicenter validation.
- It notes substantial assay heterogeneity across studies, including differences in plasma processing, cfDNA input, sequencing depth, error suppression, positivity thresholds, and handling of clonal hematopoiesis.
- It also emphasizes that low-shedding disease limits detection, so “ctDNA not detected” may reflect biology or technical sensitivity rather than true absence of disease; this is especially important in postoperative MRD and molecular relapse settings.
- Evident from the text: because this is a narrative review, its conclusions are based on selective synthesis rather than a fully systematic, quantitatively pooled evidence base.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
23 Valid · 4 Not valid · 59 Not checked · 60 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In early-stage solid tumors, ctDNA detection after curative-intent therapy has shown strong clinical validity for predicting future relapse”
What the sources say
- Supportedcites [9] Moding, 2021, Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease, Cancer Discov. source
The ‘Clinical sensitivity and specificity of current approaches’ section reviews studies testing ctDNA after curative-intent therapy for non-metastatic solid tumors and reports strong prognostic value for recurrence. It notes that a positive result has a high likelihood of relapse, while sensitivity is more limited. (LLM, conf=0.94)
- Supportedcites [10] Peng, Y., Mei, W., Ma, K., and Zeng, C. (2021). Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives. Front. Oncol., 11. source
The Colorectal Cancer section reports that postoperative ctDNA positivity in stage I–III patients was associated with a seven-fold higher recurrence risk and that positivity after adjuvant chemotherapy was associated with a seventeen-fold higher risk. The Recurrence Risk Assessment section also links ctDNA detected after cystectomy to subsequent recurrence, supporting the claim across early-stage solid tumors. (LLM, conf=0.91)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In complex-karyotype sarcomas such as osteosarcoma, undifferentiated pleomorphic sarcoma, leiomyosarcoma, and dedifferentiated liposarcoma, individualized tumor-informed approaches or genome-wide copy-number strategies may be more appropriate [ 16 , 17 ].”
What the sources say
- Partly supportedcites [16] Fu, Y., Xu, Y., Liu, W., Zhang, J., Wang, F., Jian, Q., Huang, G., Zou, C., Xie, X., and Kim, A.H. (2024). Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma. EclinicalMedicine, 73. sourceExperimental — accuracy not yet measured
The Results and Discussion support an individualized tumor-informed approach for osteosarcoma because of its mutational heterogeneity. They do not extend that recommendation to undifferentiated pleomorphic sarcoma, leiomyosarcoma, or dedifferentiated liposarcoma. The Discussion says genome-wide copy-number detection has been explored in osteosarcoma, but describes its low sensitivity as making it unsuitable for longitudinal MRD detection. Page numbers are unavailable in our copy. (LLM, conf=0.88)
- Partly supportedcites [17] Audinot, 2024, ctDNA quantification improves estimation of outcomes in patients with high-grade osteosarcoma: A translational study from the OS2006 trial, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. sourceExperimental — accuracy not yet measured
The Introduction (lines 114–120) supports genome-wide copy-number analysis for ctDNA detection in osteosarcoma. The Discussion (lines 337–350) mentions patient-specific panels used in other osteosarcoma studies, but does not establish that either approach is more appropriate across the other three named sarcomas. (LLM, conf=0.87)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“while methylation-based approaches may provide value in osteosarcoma, chordoma, and other low-mutation contexts [ 18 , 19 , 20 , 21 ].”
What the sources say
- Could not verifycites [18] Davies, 2021, Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations, Mol. Oncol. sourceExperimental — accuracy not yet measured
The Discussion addresses mutation-based ctDNA testing in chondrosarcoma and calls for additional biomarkers in tumours without IDH1/2 or GNAS mutations. Our copy does not address whether methylation-based approaches may help in osteosarcoma, chordoma, or other low-mutation contexts (searched: methylation, chordoma, osteosarcoma). (LLM, conf=0.75)
- Not checked yetcites [19] Zuccato, 2022, DNA methylation-based prognostic subtypes of chordoma tumors in tissue and plasma, Neuro-Oncology source
- Could not verifycites [20] Gutteridge, 2017, Digital PCR analysis of circulating tumor DNA: A biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection, Cancer Med. sourceExperimental — accuracy not yet measured
The Results and Discussion describe mutation-targeted digital PCR in chondrosarcoma and other bone and soft-tissue tumors. Searches for methylation-based approaches, osteosarcoma, chordoma, and low-mutation contexts found no passage assessing the claimed potential value of methylation-based methods. (LLM, conf=0.75)
- Not checked yetcites [21] Kara, 2022, Osteosarcoma: Novel prognostic biomarkers using circulating and cell-free tumour DNA, Eur. J. Cancer
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
None of the sources cited for this claim have been checked yet.
In the paper
“In the postoperative and post-treatment setting, radiologic interpretation may be further complicated by fibrosis, necrosis, inflammation, postsurgical change, and stable residual abnormalities that do not reliably distinguish treatment effect from viable disease [ 6 , 7 , 8 ].”
What the sources say
- Not checked yetcites [6] Vilanova, 2025, Soft tissue tumor imaging in adults: European Society of Musculoskeletal Radiology–Guidelines 2024: Imaging immediately after neoadjuvant therapy in soft tissue sarcoma, soft tissue tumor surveillance, and the role of interventional radiology, Eur. Radiol.
- Not checked yetcites [7] Stanborough, 2022, ACR Appropriateness Criteria® malignant or aggressive primary musculoskeletal tumor—Staging and surveillance: 2022 update, J. Am. Coll. Radiol. source
- Could not verifycites [8] Dammerer, 2020, Follow-up strategies for primary extremity soft-tissue sarcoma in adults: A systematic review of the published literature, In Vivo sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“although its clinical utility for directing treatment escalation or de-escalation remains under prospective evaluation [ 9 , 10 ].”
What the sources say
- Supportedcites [9] Moding, 2021, Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease, Cancer Discov. source
The paper’s “Future directions > Prospective clinical trials” section says that the clinical utility of ctDNA MRD for personalizing therapy in solid tumors remains to be determined and that interventional trials are underway. It specifically describes trials testing escalation and de-escalation of adjuvant or consolidation therapy. The “Adjuvant therapy to improve outcomes” section also notes limited evidence that either strategy improves patient outcomes. (LLM, conf=0.94)
- Supportedcites [10] Peng, Y., Mei, W., Ma, K., and Zeng, C. (2021). Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives. Front. Oncol., 11. source
The Challenges and Future Directions section (page not available) says ctDNA-guided adjuvant treatment may be avoided for some patients in the future, calls for additional prospective studies, and cautions against withholding treatment solely on a negative test. The Conclusion (page not available) discusses adjusting adjuvant-treatment intensity according to ctDNA findings while saying that more studies are needed to validate its clinical effectiveness. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
77 more claims · 16 with their cited sources checked
Create a free account to see all 146 claims and to verify the 165 references still open.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 51
Citations
Cites
Gronchi, A., Miah, A. B., Dei Tos, A. P., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.07.006 · Cited by 1,115
Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783
Strauss, S. J., Frezza, A. M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., Bonvalot, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1995 · Cited by 513
UK guidelines for the management of soft tissue sarcomas
Dangoor, A., Seddon, B., Gerrand, C., Grimer, R., Whelan, J., & Judson, I. (2016) · Clinical Sarcoma Research · doi:10.1186/s13569-016-0060-4 · Cited by 477
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0634 · Cited by 325
Peng, Y., Mei, W., Ma, K., & Zeng, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.763790 · Cited by 167
Shulman, D. S., Klega, K., Imamovic-Tuco, A., Clapp, A., Nag, A., Thorner, A. R., Van Allen, E., Ha, G., Lessnick, S. L., Gorlick, R., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0212-9 · Cited by 149
Harmonizing Cell-Free DNA Collection and Processing Practices through Evidence-Based Guidance
Greytak, S. R., Engel, K. B., Parpart-Li, S., Murtaza, M., Bronkhorst, A. J., Pertile, M. D., & Moore, H. M. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3015 · Cited by 140
Godsey, J. H., Silvestro, A., Barrett, J. C., Bramlett, K., Chudova, D., Deras, I., Dickey, J., Hicks, J., Johann, D. J., Leary, R., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa164 · Cited by 104
Recommendations for Cell-Free DNA Assay Validations
Lockwood, C. M., Borsu, L., Cankovic, M., Earle, J. S. L., Gocke, C. D., Hameed, M., Jordan, D., Lopategui, J. R., Pullambhatla, M., Reuther, J., et al. (2023) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2023.09.004 · Cited by 96 · cited 9×
“Future studies should report pre-analytical and analytical variables transparently, including plasma volume, tube type, processing delay, cfDNA input, limit of detection, limit of quantification, tumor fraction when available, and handling of clonal hematopoiesis [5,11,12,40].”
Influential
Research works printed but not linked: 4
- Vilanova, 2025, Soft tissue tumor imaging in adults: European Society of Musculoskeletal Radiology–Guidelines 2024: Imaging immediately after neoadjuvant therapy in soft tissue sarcoma, soft tissue tumor surveillance, and the role of interventional radiology, Eur. Radiol., 35, 3324
- Kara, 2022, Osteosarcoma: Novel prognostic biomarkers using circulating and cell-free tumour DNA, Eur. J. Cancer, 168, 1
- Young, 2024, CIRCUS: CIRCUlating tumour cells in soft tissue Sarcoma—A short report, Cancer Drug Resist., 7, 51
- Nawan, 2022, Detection and Quantification of Circulating Tumor Cells in Salvaged Blood in Surgical Osteosarcoma Patients: A Pilot Study from a Tertiary Medical Center, Biomed. Environ. Sci., 35, 366
Cited by
Still being checked.
Metadata
- Authors
- Alabid, I., Yousef, A. J., Patni, M. M., Aloti, R. A., Qassim, Z. A.-A. M., Alothman-Agha, A. A., Hamdy, H. A., Noury, F. M., & Abdelfattah, M. T.
- Affiliations
- Ras al-Khaimah Medical and Health Sciences University (AE)
- Consultant Orthopaedic and Joint Replacement Surgeon, Department of Spine and Orthopaedic Surgery, RAK Hospital, Ras Al Khaimah 11393, United Arab Emirates
- Corresponding author
- Alabid, Ibrahim
- Patni, Mohamedanas Mohamedfaruk
- ORCID
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2026-07-15
- Volume
- 15
- Issue
- 14
- Pages
- 1271
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC13407131
- OpenAlex
- W7168401412
- Cited by
- 0
- References
- 51
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- liquid biopsy, bone sarcoma, soft tissue sarcoma, osteosarcoma, circulating tumor DNA, circulating tumor cells, minimal residual disease, molecular relapse, treatment response monitoring, risk stratification
- MeSH terms
- Liquid Biopsy, Circulating Tumor DNA, Bone Neoplasms, Humans, Neoplastic Cells, Circulating, Sarcoma, Biomarkers, Tumor, Genomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas. https://app.cochat.ai/papers/10.3390/cells15141271
- The paper
- Alabid, I., Yousef, A. J., Patni, M. M., Aloti, R. A., Qassim, Z. A.-A. M., Alothman-Agha, A. A., Hamdy, H. A., Noury, F. M., & Abdelfattah, M. T. (2026). Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas. Cells. https://doi.org/10.3390/cells15141271
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.